Climb Bio (NASDAQ:CLYM) Shares Gap Up After Analyst Upgrade

Climb Bio, Inc. (NASDAQ:CLYM) gapped up before the market opened on Wednesday after HC Wainwright raised their price target on the stock from $11.00 to $15.00. The stock had previously closed at $7.33, but opened at $7.80. HC Wainwright currently has a buy rating on the stock. Climb Bio shares last traded at $7.4550, with a volume of 117,027 shares changing hands.

Several other analysts also recently weighed in on CLYM. Piper Sandler started coverage on Climb Bio in a research note on Friday, February 13th. They set an “overweight” rating for the company. Robert W. Baird lifted their price target on Climb Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, January 21st. Finally, Wedbush began coverage on Climb Bio in a research report on Thursday, March 5th. They issued an “outperform” rating and a $12.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Climb Bio currently has an average rating of “Moderate Buy” and a consensus price target of $11.40.

Insider Buying and Selling at Climb Bio

In other news, Director Ra Capital Management, L.P. bought 101,462 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were acquired at an average cost of $2.86 per share, with a total value of $290,181.32. Following the completion of the transaction, the director directly owned 3,396,318 shares in the company, valued at $9,713,469.48. This represents a 3.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.80% of the company’s stock.

Key Climb Bio News

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: HC Wainwright raised its price target on CLYM from $11 to $15 and kept a “Buy” rating — a large upside vs. the current share price, which is likely the main bullish catalyst for the stock today. Benzinga Article
• Neutral Sentiment: HC Wainwright published quarterly EPS estimates for FY2027 (Q1: -$0.26, Q2: -$0.29, Q3: -$0.31, Q4: -$0.32) and a full‑year consensus of about -$1.57. These are model-driven projections that reaffirm expected losses but also provide a roadmap for investor expectations. MarketBeat Report
• Negative Sentiment: Reports flagged a “large increase” in March short interest, but the published figures show 0 shares and NaN changes with a 0.0 days-to-cover — indicating likely data/reporting errors. If confirmed as a real short build, it could add downward pressure; as-is, the ambiguity may fuel volatility and speculative trading.

Institutional Trading of Climb Bio

Institutional investors have recently modified their holdings of the company. AQR Capital Management LLC bought a new position in Climb Bio in the first quarter worth $27,000. Goldman Sachs Group Inc. bought a new stake in Climb Bio in the 1st quarter valued at $147,000. Nan Fung Trinity HK Ltd. bought a new stake in Climb Bio in the 2nd quarter valued at $575,000. Stonepine Capital Management LLC bought a new stake in Climb Bio in the 2nd quarter valued at $144,000. Finally, Marshall Wace LLP acquired a new position in shares of Climb Bio in the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Climb Bio Stock Performance

The business’s 50 day moving average price is $5.39 and its 200-day moving average price is $3.43. The company has a market cap of $499.79 million, a price-to-earnings ratio of -8.24 and a beta of -0.25.

Climb Bio (NASDAQ:CLYM) last issued its earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.06). On average, equities research analysts expect that Climb Bio, Inc. will post -1.57 earnings per share for the current fiscal year.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.